The Philadelphia Pediatric Medical Device Consortium, or PPDC, aims to assist pediatric medical device innovators along the pathway from concept to commercialization. We provide innovators with the assistance and support needed to commercialize their technologies to improve pediatric medicine.
The PPDC is very excited to introduce its new online forum! We hope this forum will increase engagement and awareness of available tools to develop and commercialize pediatric devices.
The PPDC is proud to have an active membership composed of innovators and luminaries with a diverse range of clinical, scienctific, and industry experience. Members share the PPDC goal to bring pediatric medical devices to market.
Membership benefits include:
Details below:
Keynote Presenter: Vasum Peiris, MD, MPH, FAAP, FACC, FASE Chief Medical Officer – Pediatrics and Special Populations
Center for Devices and Radiological Health U.S. Food and Drug Administration
Program Features: Disruptive Innovation Presentations • Translation Practicums • Keynote Luncheon • Moonshot Concept Pitches • Networking
Friday, July 13, 2018, 8 am to 3 pm
University of Pittsburgh· William Pitt Union
Pittsburgh, Pennsylvania
Penn Health-Tech 2018
Innovation Spotlight Presentation
Jonathan M. Rothberg, PhD
Founder & Chief Strategy ffcer, 4Catalyzer
Adjunct Professor of Genetics, Yale School of Medicine
Pediatric patients have long been an underserved population in the technology space with many having to deal with ill-fitted medical devices and a lack of access to effective diagnostic or therapeutic devices. CTIP aims to address these unmet needs.
Mobile health (mHealth) provides unprecedented opportunities to measure dynamic changes in health state and the key physical, biological, behavioral, social, and environmental factors that contribute to health and disease risk. In the last decade, a significant number of mHealth technologies have been developed and applied to advance health research.
Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act
Draft Guidance for Industry and Food and Drug Administration Staff
